By Kelly Cloonan
Dyne Therapeutics named Erick Lucera as chief financial officer, effective March 31, adding an industry veteran of more than three decades to the biotechnology company.
Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at Aveo Pharmaceuticals and Valeritas Holdings.
Lucera will receive an annual base salary of $520,000 and will be eligible for an annual incentive bonus of up to 40% of his annualized base salary for each fiscal year, according to a filing with the Securities and Exchange Commission.
Editas promoted Amy Parison, senior vice president of finance, to succeed Lucera as CFO, effective March 28.
Parison, 39, will receive an annual base salary of $415,000 and will be eligible for an annual target bonus equal to 40% of her base salary.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
March 20, 2025 17:14 ET (21:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。